PepsRadar
⌕ Search✧ Ask
Both are short synthetic peptides developed in Russia, and neither is FDA-approved. Selank is studied for anxiety; Semax for recovery after stroke and other brain conditions. Their human evidence is small Russian clinical reports, mostly available only as abstracts.
| Fact | Selank | Semax |
|---|---|---|
| FDA status | Not FDA-approved | Not FDA-approved |
| What it is | Selank is a research peptide discussed for anxiety-related effects. Its small clinical literature needs careful attention to study design and replication. | Semax is a seven-amino-acid peptide investigated in neurobiological research. The selected study examines responses to experimental brain ischemia. |
| Human evidence | No randomized trials · Small comparative study · active-comparator study | No randomized trials · comparative study |
| Human safety data | Very limited. Not FDA-approved. Small Russian comparison studies report tolerability, but FDA says it lacks important safety information, so its risks are uncertain. | Very limited. Not FDA-approved. Human evidence is small Russian clinical reports, and FDA says it cannot tell whether Semax would cause harm, so its risks are uncertain. |
| Boxed warning | No FDA label to carry one | No FDA label to carry one |
| Serious risks |
|
|
| Conditions flagged | None flagged, because there is too little human safety data to assess | None flagged, because there is too little human safety data to assess |
| Claim check | No claim check yet | Unproven: Semax improves memory and focus in healthy people. |
Each row comes from the Selank and Semax profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.
Small human comparative study · 60 patients with phobic-anxiety or somatoform disorders.
The authors reported anxiety improvement, tolerability, and quality-of-life findings, including effects persisting a week after treatment.
Limitation: The abstract does not adequately resolve allocation, blinding, effect size, or long-term harms. It is not a placebo-controlled replication or proof of routine effectiveness across anxiety disorders.
Human active-comparator study · 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 medazepam.
The authors reported similar anxiety effects between groups, with additional anti-asthenic and psychostimulant findings for Selank.
Limitation: No placebo group or numerical effect estimates are described in the abstract. The Russian-language full article needs qualified review. This does not establish effectiveness for every anxiety disorder or safety with other psychiatric medicines.
Human comparative study · 30 treated patients with acute hemispheric ischemic stroke and 80 controls described as having comparable lesion location and severity.
The authors reported faster regression of neurological deficits, especially motor impairment, with added Semax; numerical treatment effects and confidence intervals are not provided.
Limitation: Unequal groups, unclear allocation, and limited reporting leave substantial uncertainty. The Russian-language methods require review. Acute stroke findings cannot establish memory enhancement in healthy people or modern clinical practice recommendations.
Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.
Neither has a large placebo-controlled trial in our sources. Interesting early reports, not established treatments.
PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.
Other comparisons: BPC-157 vs TB-500 · Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · CJC-1295 vs Ipamorelin · Sermorelin vs Tesamorelin · MOTS-c vs Elamipretide · Ipamorelin vs MK-677 · AOD-9604 vs HGH Fragment 176-191 · Thymosin alpha-1 vs Thymosin beta-4 · Tesamorelin vs CJC-1295 · GHK-Cu vs AHK-Cu · Epitalon vs Pinealon
See something wrong on this page? Report a mistake · Corrections